Security Notice: Please be aware of impersonation attempts using our company name
Legitimate communications from Ascent Research will only come from official @ascentresearch.com email addresses.
Quick Order Cart

Cat. No. ARG0543

GSDMC Knockout MCF-7 Cell Line

  • Product Type:

    Genome-edited Cells

  • Tissue Source:

    Breast (mammary gland)

  • Disease:

    Adenocarcinoma

  • Gene Species:

    Homo sapiens (Human)

The GSDMC Knockout MCF-7 Cell Line is a CRISPR/Cas9-edited human cell line lacking functional GSDMC, a pyroptosis executioner that forms membrane pores upon cleavage by caspase-8 downstream of TNF-alpha/TNFR1 signaling. Derived from the ER+ MCF-7 breast adenocarcinoma line, this model enables dissection of inflammatory cell death mechanisms in a hormone-responsive cancer background. It is ideal for investigating pyroptosis induction, IL-1beta and IL-18 release, and drug sensitivity. Applications include LDH release assays, ELISA, flow cytometry, and xenograft studies, offering insights into TNF-alpha-driven cell death and breast cancer biology. Contact Ascent Research for more information.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    MCF-7

    Morphology

    Epithelial-like

    Age

    69 years

    Sex of Donor

    Female

    Gene Name

    GSDMC

    Gene Species

    Homo sapiens (Human)

    Gene Identifier

    NCBI Gene ID 56169

  • Culture Conditions

    Temperature

    37°C

    Atmosphere

    5% CO₂

  • Quality Control

    Sterility testing

    Daily monitoring confirms that the cells are free from bacterial, yeast, and fungal contamination.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

    Pathogens

    Cells tested negative for HIV-1, HBV, and HCV.

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

The GSDMC Knockout MCF-7 Cell Line is a CRISPR/Cas9-edited human cell line that carries a targeted disruption of the GSDMC gene, resulting in a loss-of-function model for studying pyroptosis and inflammatory cell death. MCF-7 cells, derived from a metastatic mammary adenocarcinoma, serve as a well-established estrogen receptor-positive (ER+) breast cancer model. This knockout cell line provides a genetically defined system to dissect the molecular mechanisms governing GSDMC-mediated pore formation and downstream cytokine release. MCF-7 cells are adherent epithelial cells originally isolated from the pleural effusion of a patient with metastatic breast adenocarcinoma. They retain expression of estrogen receptor alpha (ER??) and are widely used to model luminal A breast cancer, hormone responsiveness, and metastatic progression. The cells exhibit typical epithelial morphology and are sensitive to hormonal and chemotherapeutic agents, making them a versatile platform for both fundamental and translational oncology research. GSDMC encodes a member of the gasdermin family that functions as a key executioner of pyroptosis, a lytic and highly inflammatory form of programmed cell death. Upon activation of the TNF-alpha/TNFR1 signaling axis, caspase-8 cleaves GSDMC, liberating its N-terminal domain. This fragment then translocates to and oligomerizes within the plasma membrane, forming pores that disrupt cellular ionic homeostasis, drive osmotic swelling, and ultimately cause membrane rupture. The process culminates in the extracellular release of pro-inflammatory cytokines such as IL-1beta and IL-18, along with alarmins including HMGB1 and LDH. Upstream regulators such as TGF-beta, STAT3, NF-kB, and IL-1beta modulate GSDMC expression and activity, placing the protein at a nexus of cell death and inflammatory signaling. Interaction with caspase-1 and caspase-4 further diversifies its activation landscape. In breast cancer, particularly the ER+ subtype represented by MCF-7 cells, GSDMC-mediated pyroptosis shapes the tumor microenvironment and therapeutic response. Loss of GSDMC function may alter sensitivity to TNF-alpha-mediated cytotoxicity and influence the immunogenicity of dying cells. This knockout model enables dissection of how GSDMC-dependent pore formation affects drug-induced cell death, cytokine release profiles, and the balance between apoptosis and pyroptosis, with potential implications for tumor progression and metastasis. Typical research applications include quantifying pyroptosis by flow cytometry and LDH release, measuring IL-1beta and IL-18 secretion via ELISA, and assessing caspase-8 activity following TNF-alpha stimulation. The cell line is also suitable for Western blot and RT-qPCR to confirm GSDMC disruption and for functional assays such as MTT cell viability, Transwell migration/invasion, and drug sensitivity testing with doxorubicin or TNF-alpha. Immunofluorescence visualization of GSDMC-N pore complexes and tumor xenograft studies further expand its utility. For further technical details or to discuss experimental applications, please contact Ascent Research.
Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)